3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
2
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Breast Neoplasms
12
Neoplasm Metastasis
6
Glioblastoma
4
Triple Negative Breast Neoplasms
3
Brain Neoplasms
3
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasms
2
Hereditary Sensory and Autonomic Neuropathies
2
Carcinoma, Non-Small-Cell Lung
2
Treatment for Metastatic or Locally Advanced Cervical Cancer
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Recurrence
1
Pre-menopausal Breast Cancer
1
Non-Small Cell Lunch Cancer
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Locally Advanced Solid Tumor
1
Leukemia, Myeloid, Acute
1
Hematologic Neoplasms
1
Head and Neck Neoplasms
1
Gliosarcoma
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Interventions
pembrolizumab
72
Cisplatin
57
Cetuximab
38
Fluorouracil
25
Nivolumab
21
Radiotherapy
20
Carboplatin
19
Paclitaxel
14
Docetaxel
11
Cyclophosphamide
9
Gefitinib
8
fludarabine
7
durvalumab
7
zalutumumab
6
atezolizumab
6
Drug Therapy
6
Bleomycin
6
epacadostat
5
cemiplimab
5
Radiotherapy, Intensity-Modulated
5
Pemetrexed
5
Ipilimumab
5
Gemcitabine
5
Afatinib
5
spartalizumab
4
Standard of Care
4
Radiation
4
Injections
4
Immune Checkpoint Inhibitors
4
Fibroblast Growth Factor 7
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Head and Neck Neoplasms
×
NVP-BKM120
×
Clear all
NCT04338399
2025-11-17
BURAN
Adlai Nortye Biopharma Co., Ltd.
Phase 3
Completed
487 enrolled